ArticleBreast cancer research : BCR2026
Tamoxifen-pretreated MSC exosomes promote endocrine resistance in ER-positive breast cancer cells through the miR-137/Serpina3 axis: a mechanistic study.
Article in Breast cancer research : BCR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundTamoxifen (TAM) resistance remains a challenge in estrogen receptor-positive breast cancer treatment. Current research suggested that mesenchymal stem cells (MSCs) derived exosomes may mediate chemoresistance, but the underlying mechanisms are unclear. This study investigates how exosomes from tamoxifen-pretreated MSCs (Tt-MSC-exos) promote tamoxifen resistance through the miR-137/SERPINA3 axis.
methodsWe isolated exosomes using ultracentrifugation. To investigate the effect of Tt-MSC-exos on TAM resistance, we co-cultured Tt-MSC-exos with ER-positive breast cancer cells and evaluated the cellular functional changes and apoptosis levels. Second-generation transcriptome sequencing was used to analyze the key genes for TAM resistance, and a dual luciferase reporter assay was used to detect the upstream factors of the key genes. The results were further validated by cellular function assays, xenograft modeling studies, and database analysis.
resultsWe demonstrated that Tt-MSC-exos promote TAM resistance in ER-positive breast cancer cells. Next-generation sequencing revealed that the key gene for Tt-MSC-exos promoting resistance was SERPINA3. Downregulation of SERPINA3 expression enhances TAM resistance in breast cancer cells. In addition, we found that miR-137, which was highly expressed in Tt-MSC-exos, could bind to the 3' UTR region of SERPINA3 in breast cancer cells and thus inhibit the expression of SERPINA3.
conclusionsIn this study, we clarified that Tt-MSC-exos inhibit the expression level of SERPINA3 in cancer cells by delivering miR-137 to ER-positive breast cancer cells, which in turn leads to TAM resistance in breast cancer. This study provides a new idea to overcome endocrine therapy resistance in ER-positive breast cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.